Balance Sheet
Cash Flow Statement
Cash from Financing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in CashDepreciation & Amortization (CF)Exchange Rate EffectFree Cash FlowGains from Investment SecuritiesGains from Sales and DivestituresNet Cash FlowNet IncomeNon-cash ItemsShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Moleculin Biotech (MBRX) Net Cash Flow (2016 - 2025)

Moleculin Biotech's Net Cash Flow history spans 10 years, with the latest figure at $2.1 million for Q4 2025.

  • Quarterly results put Net Cash Flow at $2.1 million for Q4 2025, up 141.74% from a year ago — trailing twelve months through Dec 2025 was $4.5 million (up 123.64% YoY), and the annual figure for FY2025 was $4.5 million, up 123.64%.
  • Net Cash Flow for Q4 2025 was $2.1 million at Moleculin Biotech, up from -$848000.0 in the prior quarter.
  • In the past five years, Net Cash Flow ranged from a high of $71.1 million in Q1 2021 to a low of -$8.1 million in Q2 2022.
  • The 5-year median for Net Cash Flow is -$4.9 million (2022), against an average of -$312000.0.
  • The sharpest move saw Net Cash Flow skyrocketed 7091.51% in 2021, then tumbled 396.77% in 2024.
  • Year by year, Net Cash Flow stood at -$4.3 million in 2021, then plummeted by 69.93% to -$7.3 million in 2022, then surged by 85.9% to -$1.0 million in 2023, then tumbled by 396.77% to -$5.1 million in 2024, then skyrocketed by 141.74% to $2.1 million in 2025.
  • According to Business Quant data, Net Cash Flow over the past three periods came in at $2.1 million, -$848000.0, and -$159000.0 for Q4 2025, Q3 2025, and Q2 2025 respectively.